

449 REPRODUCED

INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION

June 19, 2006

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
3474.1001-011APPLICATION NO.:
10/791,223FIRST NAMED INVENTOR
Mel H. EpsteinFILING DATE
March 2, 2004EXAMINER
Not assignedCONFIRMATION NO.
3953GROUP
1614

U.S. PATENT DOCUMENTS

| EXAM- INER INTI- TIAL | REF. NO. | DOCUMENT NUMBER Number-Kind Code (if known) | ISSUE DATE / PUBLICATION DATE MM-DD-YYYY | NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT |
|--------------------------------|-------------|------------------------------------------------|------------------------------------------------|----------------------------------------------------|
| BY | A1 | 2002/0066457 | 06-06-2002 | Landfield, <i>et al.</i> |
| | A2 | 2,828,343 | 03-25-1958 | Tindall, J. B. |
| | A3 | 3,728,445 | 04-17-1973 | Bardani |
| | A4 | 3,996,381 | 12-07-1976 | Florvall, <i>et al.</i> |
| | A5 | 4,034,113 | 07-05-1977 | Shulgin |
| | A6 | 4,105,695 | 08-08-1978 | Partyka, R. A., <i>et al.</i> |
| | A7 | 4,479,932 | 10-30-1984 | Bodor, N. S. |
| | A8 | 4,598,094 | 07-01-1986 | Wurtman, R. J., <i>et al.</i> |
| | A9 | 4,636,494 | 06-13-1987 | Growdon, J. H., <i>et al.</i> |
| | A10 | 4,647,591 | 03-03-1987 | Cherkin, <i>et al.</i> |
| | A11 | 5,019,594 | 05-28-1991 | Wurtman, R. J., <i>et al.</i> |
| | A12 | 5,075,338 | 12-24-1991 | Knoll, <i>et al.</i> |
| | A13 | 5,096,712 | 03-17-1992 | Wurtman, R. J. |
| | A14 | 5,151,449 | 09-29-1992 | Milgram |
| | A15 | 5,220,068 | 06-15-1993 | Knoll, <i>et al.</i> |
| | A16 | 5,225,446 | 07-06-1993 | Milgram |
| | A17 | 5,422,355 | 06-06-1995 | White, <i>et al.</i> |
| | A18 | 5,684,018 | 11-04-1997 | Alexander, J. |
| | A19 | 5,914,129 | 06-22-1999 | Mauskop, A. |
| | A20 | 6,204,245 B1 | 03-20-2001 | Siegel, J. M., <i>et al.</i> |
| | A21 | 6,228,875 B1 | 05-08-2001 | Tsai, G., <i>et al.</i> |
| | A22 | 6,251,938 B1 | 06-26-2001 | Chorev, M., <i>et al.</i> |
| | A23 | 6,284,760 B1 | 09-04-2001 | Marston, H. M., <i>et al.</i> |
| | A24 | 6,451,806 | 09-17-2002 | Farrar |
| | A25 | 6,492,427 B2 | 12-10-2002 | Shankar, <i>et al.</i> |
| ✓ | A26 | 6,635,675 B2 | 10-21-2003 | Kranzler, <i>et al.</i> |

EXAMINER

/Brian Yong Kwon/

DATE CONSIDERED

01/24/2007

| | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|--------------------------------|------------------------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 3474.1001-011 | APPLICATION NO.: 10/791,223 | |
| | FIRST NAMED INVENTOR Mel H. Epstein | | FILING DATE March 2, 2004 |
| | EXAMINER Not assigned | CONFIRMATION NO. 3953 | GROUP 1614 |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|------------------------------------------------------------------------|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BY | C1 | Alafuzoff, I., <i>et al.</i> , "Selegiline Treatment and the Extent of Degenerative Changes in Brain Tissue of Patients with Alzheimer's Disease," <i>Eur. J. Clin. Pharmacol.</i> , 55:815-819 (2000). |
| | C2 | Alles, G. A., "Comparative Physiological Actions of the Optically Isomeric Phenisopropylamines," <i>University of California Publications in Pharmacology</i> , 129-150 (1939). |
| | C3 | Angrist, and Gershon, "Relationship Between Symptoms and Urinary Levels of Amphetamine," <i>Some Recent Studies of Amphetamine Psychosis - Unresolved Issues</i> , 197-203. |
| | C4 | Angrist, B. M., <i>et al.</i> , "Comparative Psychotomimetic Effects of Stereoisomers of Amphetamine," <i>Nature</i> , 234:152-153 (1971). |
| | C5 | Anisman, H. and Waller, T. G., "Effects of Methamphetamine and Shock Duration During Inescapable Shock Exposure on Subsequent Active and Passive Avoidance," <i>J. Comp. Physiol. Psychol.</i> , 77(1):143-151 (1971). |
| | C6 | Arakawa, O., "Effects of Methamphetamine and Methylphenidate on Single and Paired Rat Open-Field Behaviors," <i>Physiol. Behav.</i> , 55(3):441-446 (1994). |
| | C7 | Arnold, L. E., "Levoamphetamine vs Dextroamphetamine in Minimal Brain Dysfunction," <i>Arch. Gen. Psychiatry.</i> , 33:292-301 (1976). |
| | C8 | Arnold, L. E., "Levoamphetamine and Dextroamphetamine: Comparative Efficacy in the Hyperkinetic Syndrome," <i>Arch. Gen. Psychiat.</i> , 27:816-822 (1972). |
| | C9 | Axelrod, J., "Amphetamine: Metabolism, Physiological Disposition and It's Effects on Catecholamine Storage," <i>Amphetamines and Related Compounds</i> , 207-216 (1970). |
| | C10 | Axelrod, J., "The Enzymatic Deamination of Amphetamine (Benzedrine)," <i>Laboratory of Chemical Pharmacology</i> , 753-763 (1954). |
| | C11 | Axelrod, J., <i>et al.</i> , "Effect of Psychotropic Drugs on the Uptake of H ³ -Norepinephrine by Tissues," <i>Science</i> , 133:383-384 (1961). |
| ✓ | C12 | Balster, R. L., <i>et al.</i> , "A Comparison of <i>d</i> -Amphetamine, <i>l</i> -Amphetamine, and Methamphetamine Self-administration in Rhesus Monkeys," <i>Pharm. Biochem. Behav.</i> , 1:67-71 (1973). |

| | |
|-----------------------------------|-------------------------------|
| EXAMINER /Brian Yong Kwon/ | DATE CONSIDERED 01/24/2007 |
|-----------------------------------|-------------------------------|

| | | | | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|--|---------------------------------------|----------------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 3474.1001-011 | | APPLICATION NO.: 10/791,223 | |
| | FIRST NAMED INVENTOR Mel H. Epstein | | FILING DATE March 2, 2004 | |
| | EXAMINER Not assigned | | CONFIRMATION NO. 3953 | GROUP 1614 |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|------------------------------------------------------------------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BY | C13 | Barch, D. M., <i>et al.</i> , "The Effects of D-Amphetamine on Language Function in Schizophrenia," <i>Society for Neuroscience Abstracts</i> 23(1-2):p. 1952 (1997). |
| | C14 | Bartus, R. T., "Drugs to Treat Age-Related Neurodegenerative Problems," <i>JAGS</i> , 38(6):680-695 (1990). |
| | C15 | Bartzokis, G., <i>et al.</i> , "Selegiline Effects on Cocaine-Induced Changes in Medial Temporal Lobe Metabolism and Subjective Ratings of Euphoria," <i>Neuropsychopharmacology</i> , 20(6): 582-590 (1999). |
| | C16 | Batterman, R.C., "Studies with Levo-Desoxyephedrine," Combination Report to the Vicks Chemical Company, March 4, 1965. |
| | C17 | Bauer, R. and Evey, L., "Differential Effects of L-Amphetamine on Ontogeny of Active Avoidance, Intertitial Responses, and Locomotor Activity," <i>Psychopharmacology</i> 75: 299-304 (1981). |
| | C18 | Beckett, A. H. and Rowland, M., "Urinary Excretion Kinetics of Amphetamine in Man," <i>J. Pharm. Pharmacol.</i> 17:628-639 (1965). |
| | C19 | Beckett, A. M., <i>et al.</i> , "Metabolic Oxidation on Aliphatic Basic Nitrogen Atoms and Their α -carbon Atoms-Some Unifying Principles," <i>Letters to the Editor, J. Pharm. Pharmac.</i> 23:809-812 (1971). |
| | C20 | Berlyne, D. E., "Arousal, Reward and Learning," <i>Ann. N. Y. Acad. Sci.</i> , 159(3):1059-1070 (1969). |
| | C21 | Biel, J. H., "Structure-Activity Relationships of Amphetamine and Derivatives," <i>Amphetamines and Related Compounds</i> , 3-19 (1970). |
| | C22 | Biel, J. H. and Bopp, B. A., "Amphetamines: Structure-Activity Relationships," in <i>The Handbook of Psychopharmacology</i> , Vol. 11, stimulants, L. L. Iversen, S. D. Iverson. and S. H. Snyder. Eds.. Plenum Publishing Company, New York, 1978, pp. 1-39. |
| | C23 | Birkmayer, W., "Long Term Treatment With L-Deprenyl," <i>J. Neural Transm.</i> , 43:239-244 (1978). |
| | C24 | Birks, J. and Flicker, L., "Selegiline For Alzheimer's Disease," (Cochrane Review). In: <i>The Cochrane Library, Issue 2</i> (2002). Oxford: Update Software. |
| ✓ | C25 | Bisagno, V., <i>et al.</i> , "Short Toxic Methamphetamine Schedule Impairs Object Recognition Task in Male Rats," <i>Brain Res.</i> , 940:95-101 (2002). |

| | |
|------------------------------------------|--------------------------------------|
| EXAMINER /Brian Yong Kwon/ | DATE CONSIDERED 01/24/2007 |
|------------------------------------------|--------------------------------------|

| | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|--------------------------------|------------------------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 3474.1001-011 | APPLICATION NO.: 10/791,223 | |
| | FIRST NAMED INVENTOR Mel H. Epstein | | FILING DATE March 2, 2004 |
| | EXAMINER Not assigned | CONFIRMATION NO. 3953 | GROUP 1614 |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|----|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BY | C26 | Bishop, J., <i>et al.</i> , "Toxicology and Carcinogenesis Studies of <i>dl</i> -Amphetamine Sulfate in F344/N Rats and B6C3F ₁ Mice," (Technical Report Series No. 387). Research Triangle Park, NC: National Toxicology Program, U. S. Department of Health and Human Services (1991). |
| | C27 | Blaug, S. M. and Huang W.-T., "Interaction of Dextroamphetamine Sulfate with Spray-Dried Lactose," <i>J. Pharm. Sci.</i> , 61(11):1770-1775 (1972). |
| | C28 | Bodkin, J. A. and Amsterdam, J. D., "Transdermal Selegiline in Major Depression: A Double-Blind, Placebo-Controlled, Parallel-Group Study in Outpatients," <i>Am. J. Psychiatry</i> , 159(11):1869-1875 (2002). |
| | C29 | Brandeis, R. <i>et al.</i> , "Improvement of Cognitive Function by MAO-B Inhibitor L-Deprenyl in Aged Rats," <i>Pharmacol. Biochem. Behav.</i> , 39:297-304 (1991). |
| | C30 | Bromage, P. R., "Comparison of Vasoactive Drugs in Man," <i>Bri. Med. J.</i> , 72-74 (July 12, 1952). |
| | C31 | Brown, G. L., "Plasma Levels of <i>d</i> -Amphetamine in Hyperactive Children," <i>Psychopharmacology</i> , 62:133-140 (1979). |
| | C32 | Brown, R. W., <i>et al.</i> , "D-amphetamine Facilitation of Morris Water Task Performance is Blocked by Eticlopride and Correlated with Increased Dopamine Synthesis in the Prefrontal Cortex," <i>Behav. Brain Res.</i> , 114:135-143 (2000). |
| | C33 | Browne, R. G. and Segal, D. S., "Metabolic and Experiential Factors in the Behavioral Response to Repeated Amphetamine," <i>Pharmacol. Biochem. Behav.</i> , 6:545-552 (1977). |
| | C34 | Burešová, O. and Bureš, J., "Radial Maze as a Tool for Assessing the Effect of Drugs on the Working Memory of Rats," <i>Psychopharmacology</i> , 77:268-271 (1982). |
| | C35 | CA Index Name: "Benzeneethanamine, α -methyl-, (α S)-(9Cl)", <i>SciFinder Scholar</i> , Registry Number: 51-64-9 (1p.) (2001). |
| | C36 | Caldwell, J., <i>et al.</i> , "Metabolism of [¹⁴ C]Methamphetamine in Man, the Guinea Pig and the Rat," <i>Biochem. J.</i> , 129:11-22 (1972). |
| ✓ | C37 | Cappon, G. D. and Vorhees, C. V., "Plasma and Brain Methamphetamine Concentrations in Neonatal Rats," <i>Neurotoxicol. Teratol.</i> , 23:81-88 (2001). |

| | |
|-----------------------------------|-----------------------------------|
| EXAMINER /Brian Yong Kwon/ | DATE CONSIDERED 01/24/2007 |
|-----------------------------------|-----------------------------------|

| | | | | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|--|---------------------------------------|----------------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 3474.1001-011 | | APPLICATION NO.: 10/791,223 | |
| | FIRST NAMED INVENTOR Mel H. Epstein | | FILING DATE March 2, 2004 | |
| | EXAMINER Not assigned | | CONFIRMATION NO. 3953 | GROUP 1614 |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|------------------------------------------------------------------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BY | C38 | Carr, G. D. and White, N. M., "The Relationship Between Stereotypy and Memory Improvement Produced by Amphetamine," <i>Psychopharmacology</i> 82:203-209 (1984). |
| | C39 | Chang, L., <i>et al.</i> , "Perfusion MRI and Computerized Cognitive Test Abnormalities in Abstinent Methamphetamine Users," <i>Psychiatry Research Neuroimaging</i> , 114:65-79 (2002). |
| | C40 | Chapman, D. E., <i>et al.</i> , "Long-Term Changes in Basal Ganglia Function After a Neurotoxic Regimen of Methamphetamine," <i>J. Pharmacol. Exp. Ther.</i> , 296(2):520-527 (2001). |
| | C41 | Cho, D., <i>et al.</i> , "Behavioral Teratogenicity of Methamphetamine," Department of Toxicology, National Institute of Safety Research, Seoul, Korea., <i>Journal Toxicol. Sci.</i> , 16 (Supp. 1):37-49 (1991). |
| | C42 | Chrisp, P., <i>et al.</i> , "Selegiline: A Review of its Pharmacology, Symptomatic Benefits and Protective Potential in Parkinson's Disease," <i>Drugs & Aging</i> , 1(3):228-248 (1991). |
| | C43 | Clement, B., <i>et al.</i> , "Reduction of Amphetamine Hydroxylamine and Other Aliphatic Hydroxylamines by Benzamidoxime Reductase and Human Liver Microsomes," <i>Chem. Res. Toxicol.</i> , 13:1037-1045 (2000). |
| | C44 | Cochran, J. C., <i>et al.</i> , "Parsing Attentional Components During a Simple Reaction Time Task Using Sleep Deprivation and Amphetamine Intervention," <i>Precet. Mot. Skills</i> , 75:675-689 (1992). |
| | C45 | Cochran, J. C., <i>et al.</i> , "Decoupling Motor Memory Strategies: Effects of Sleep Deprivation and Amphetamine," <i>Intern. J. Neurosci.</i> , 74:45-54 (1994). |
| | C46 | Cody, J. T. and Schwarzhoff, R., "Interpretation of Methamphetamine and Amphetamine Enantiomer Data," <i>J. Anal Toxicol.</i> , 17:321-326 (October, 1993). |
| | C47 | Cody, J. T., "Metabolic Precursors to Amphetamine and Methamphetamine," <i>Forensic Sci. Rev.</i> , 5(2):110-127 (1993). |
| | C48 | Comer, S. D., <i>et al.</i> , "Effects of Repeated Oral Methamphetamine Administration in Humans," <i>Psychopharmacology</i> , 155:397-404 (2001). |
| | C49 | Cook, C. E., <i>et al.</i> , Pharmacokinetics of Oral Methamphetamine and Effects of Repeated Daily Dosing in Humans," <i>Drug Metab. Dispos.</i> , 20(6):856-862 (1992). |
| ↓ | C50 | Cook, C. E., <i>et al.</i> , "Pharmacokinetics of Methamphetamine Self-Administered to Human Subjects by Smoking S-(+)-Methamphetamine Hydrochloride," <i>Drug Metab. Dispos.</i> , 21(4):717-723 (1993). |

| | |
|--------------------------------------|--------------------------------------|
| EXAMINER /Brian Yong Kwon/ | DATE CONSIDERED 01/24/2007 |
|--------------------------------------|--------------------------------------|

| | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|--|--------------------------------|---------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 3474.1001-011 | | APPLICATION NO.: 10/791,223 | |
| | FIRST NAMED INVENTOR Mel H. Epstein | | FILING DATE March 2, 2004 | |
| | EXAMINER Not assigned | | CONFIRMATION NO. 3953 | GROUP 1614 |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|------------------------------------------------------------------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BY | C51 | Cooke, B. J. A., "Chirality of Methamphetamine and Amphetamine From Workplace Urine Samples," <i>J. Anal Toxicol.</i> , 18:49-51 (1994). |
| | C52 | Cookson, J. and Silverstone, T., "The Effects of Methamphetamine on Mood and Appetite in Depressed Patients: A Placebo-controlled Study," <i>Int. Clin. Psychopharmacol.</i> , 1:127-133 (1986). |
| | C53 | Corsi-Cabrera, M., <i>et al.</i> , "Gender Differences in the EEG During Cognitive Activity," <i>Intern. J. Neurosci.</i> 72:257-264 (1993). |
| | C54 | Courtney, K. D. and Valerio, D.A., "Teratology in the <i>Macaca mulatta</i> ," <i>Teratology</i> , 1:163-172 (1968). |
| | C55 | Crabbe, J. C. and Alpern, H. P., "d-Amphetamine: Disruptive Effects on the Long-Term Store of Memory and Proactive Facilitatory Effects on Learning in Inbred Mice," <i>Pharmacol. Biochem. Behav.</i> , 3:647-652 (1975). |
| | C56 | Croce, P. D., <i>et al.</i> , "A Simple Procedure for N-Propenylation and N-Propynylation of Secondary Amines," <i>Gazzetta Chimica Italiana</i> , 126:107-109 (1996). |
| | C57 | Csanda, E., <i>et al.</i> , "Experiences With L-Deprenyl in Parkinsonism," <i>J. Neural Transm.</i> , 43:263-269 (1978). |
| | C58 | Czub, M., <i>et al.</i> , "Effects of Selegiline in a Retroviral Rat Model for Neurodegenerative Disease," <i>J. NeuroVirol.</i> , 5:458-464 (1999). |
| | C59 | Davis, J. M., <i>et al.</i> , "Effects of Urinary pH on Amphetamine Metabolism," <i>Ann. N.Y. Acad. Sci.</i> , 179:493-501 (1971). |
| | C60 | DeLuca, J., "Cognitive Dysfunction After Aneurysm of the Anterior Communicating Artery," <i>J. Clin. Exp. Neuropsychol.</i> , 14(6):924-934 (1992). |
| | C61 | Dixit, S. N., <i>et al.</i> , "Effect of Selegiline on Cognitive Functions in Parkinson's Disease," <i>JAPI</i> , 47(8):784-786 (1999). |
| | C62 | Donnan, P. T., <i>et al.</i> , "Selegiline and Mortality in Subjects with Parkinson's Disease: a Longitudinal Community Study," (Reply from the authors), <i>Neurology</i> , 57(2): Correspondence (2001). |
| ↓ | C63 | Dring, L. G., <i>et al.</i> , "The Metabolic Fate of Amphetamine in Man and Other Species," <i>Biochem. J.</i> , 116:425-435 (1970). |

| | |
|-------------------------------|-------------------------------|
| EXAMINER /Brian Yong Kwon/ | DATE CONSIDERED 01/24/2007 |
|-------------------------------|-------------------------------|

| | | | | |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|--|---------------------------------------|----------------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 3474.1001-011 | | APPLICATION NO.: 10/791,223 | |
| | FIRST NAMED INVENTOR Mel H. Epstein | | FILING DATE March 2, 2004 | |
| | EXAMINER Not assigned | | CONFIRMATION NO. 3953 | GROUP 1614 |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|------------------------------------------------------------------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BY | C64 | Dring, L. G., <i>et al.</i> , "The Fate of Amphetamine in Man and Other Mammals," <i>Letters to the Editor, J. Pharm. Pharmac.</i> 18:402-405 (1966). |
| | C65 | Dringenberg, H. C., <i>et al.</i> , "Increased Effectiveness of Tacrine by Deprenyl Co-treatment in Rats: EEG and Behavioral Evidence," <i>Neuropharmacology and Neurotoxicology</i> , 11(16):3513-3516 (2000). |
| | C66 | Ebadi, M., <i>et al.</i> , "Neuroprotective Actions of Selegiline," <i>J. Neurosci. Res.</i> , 67:285-289 (2002). |
| | C67 | Ebert, U. and Kirch, W., "Scopolamine Model of Dementia: Electroencephalogram Findings and Cognitive Performance," <i>Eur. J. Clin. Invest.</i> , 28:944-949 (1998). |
| | C68 | Elsworth, J. D., <i>et al.</i> , "The Contribution of Amphetamine Metabolites of (-)-Deprenyl to Its Antiparkinsonian Properties," <i>J. Neural Transm.</i> , 54:105-110 (1982). |
| | C69 | Ernst, M., <i>et al.</i> , "Selegiline in ADHD Adults: Plasma Monoamines and Monoamine Metabolites," <i>Neuropsychopharmacology</i> , 16(4):276-284 (1997). |
| | C70 | Ernst, M., <i>et al.</i> , "Selegiline in Adults With Attention Deficit Hyperactivity Disorder: Clinical Efficacy and Safety," <i>Psychopharmacol. Bull.</i> , 32(3):327-334 (1996). |
| | C71 | Falsaperla, A., <i>et al.</i> , "Selegiline Versus Oxiracetam in Patients With Alzheimer-Type Dementia," <i>Clinical Therapeutics</i> , (12)5:376-384, (1990). |
| | C72 | Fang, J. and Yu, P. H., "Effect of L-Deprenyl, its Structural Analogues and Some Monoamine Oxidase Inhibitors on Dopamine Uptake," <i>Neuropharmacology</i> , 33(6):763-768 (1994). |
| | C73 | Ferrando, R. L., <i>et al.</i> , "Bizarre Behavior Following the Ingestion of Levo-Desoxyephedrine," <i>Drug Intelligence and Clinical Pharmacy</i> , 22:214-216 (1988). |
| | C74 | Filip, V. and Kolibas, E., "Selegiline in the Treatment of Alzheimer's Disease: a Long-Term Randomized Placebo-Controlled Trial," <i>J. Psychiatry Neurosci.</i> , 24(3):234-243 (1999). |
| | C75 | Finali, G., <i>et al.</i> , "L-Deprenyl Therapy Improves Verbal Memory in Amnesic Alzheimer Patients," <i>Clin. Neuropharmacol.</i> , 14(6):523-536 (1991). |
| ✓ | C76 | Finali, G., <i>et al.</i> , "Alzheimer-type Dementia and Verbal Memory Performances: Influence of Selegiline Therapy," <i>Ital. J. Neurol. Sci.</i> , 13:141-148 (1992). |

| | |
|--------------------------------------|--------------------------------------|
| EXAMINER /Brian Yong Kwon/ | DATE CONSIDERED 01/24/2007 |
|--------------------------------------|--------------------------------------|

| | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|--------------------------|--------------------------------|--|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 3474.1001-011 | | APPLICATION NO.: 10/791,223 | |
| | FIRST NAMED INVENTOR Mel H. Epstein | | FILING DATE March 2, 2004 | |
| | EXAMINER Not assigned | CONFIRMATION NO. 3953 | GROUP 1614 | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|------------------------------------------------------------------------|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BY | C77 | Finkelstein, J. E., <i>et al.</i> , "Milacemide Treatment in Mice Enhances Acquisition of a Morris-Type Water Maze Task," <i>Pharmacol. Biochem. Behav.</i> , 49(3):707-710 (1994). |
| | C78 | Fitzgerald, R. L., <i>et al.</i> , "Resolution of Methamphetamine Stereoisomers in Urine Testing: Urinary Excretion of R(-)-Methamphetamine Following Use of Nasal Inhalers," <i>J. Anal. Toxicol.</i> , 12:255-259 (Sept-Oct. 1988). |
| | C79 | Fleming, K., <i>et al.</i> , "Neuropsychological Effects of Amphetamine May Correlate with Personality Characteristics," <i>Psychopharmacol. Bull.</i> , 31(2):357-362 (1995). |
| | C80 | Foster, B. S. and Gilbert, D. D., "Enantiomeric Determination of Amphetamine and Methamphetamine in Urine by Precolumn Derivatization with Marfey's Reagent and HPLC," <i>J. Anal. Toxicol.</i> , 22:265-269 (1998). |
| | C81 | Fowler, J. S., <i>et al.</i> , "Evidence That L-deprenyl Treatment for One Week Does Not Inhibit MAO A or the Dopamine Transporter in the Human Brain," <i>Life Sci.</i> , 68:2759-2768 (2001). |
| | C82 | Gelowitz, D. L., <i>et al.</i> , "Chronic L-Deprenyl or L-Amphetamine: Equal Cognitive Enhancement, Unequal MAO Inhibition," <i>Pharmacol. Biochem. Behav.</i> , 47:41-45 (1994). |
| | C83 | Gibbs, M. E., "Effects of Amphetamine on Short-Term, Protein-Independent, Memory in Day-Old Chickens," <i>Pharmacol. Biochem. Behav.</i> , 4:305-309 (1976). |
| | C84 | Glennon, R. A., <i>et al.</i> , "A Preliminary Behavioral Investigation of PMMA, the 4-Methoxy Analog of Methamphetamine," <i>Pharmacol. Biochem. Behav.</i> , 31:9-13 (1988). |
| | C85 | Golbe, L. I., <i>et al.</i> , "Selegiline and Parkinson's Disease: Protective and Symptomatic Considerations," <i>Drugs</i> , 39(5):646-651 (1990). |
| | C86 | Gold, P. E., <i>et al.</i> , "Modulation of Long-Term Potentiation by Peripherally Administered Amphetamine and Epinephrine," <i>Brain Res.</i> , 305:103-107 (1984). |
| | C87 | Goldstein, L. B., "Effects of Amphetamines and Small Related Molecules on Recovery After Stroke in Animals and Man," <i>Neuropharmacology</i> 39:852-859 (2000). |
| ✓ | C88 | Gordon, M. N., <i>et al.</i> , "Oral Versus Transdermal Selegiline: Antidepressant-Like Activity in Rats," <i>Pharmacol. Biochem. Behav.</i> , 63(3):501-506 (1999). |

| | |
|-------------------------------|-------------------------------|
| EXAMINER /Brian Yong Kwon/ | DATE CONSIDERED 01/24/2007 |
|-------------------------------|-------------------------------|

| | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|--------------------------|--------------------------------|--|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 3474.1001-011 | | APPLICATION NO.: 10/791,223 | |
| | FIRST NAMED INVENTOR Mel H. Epstein | | FILING DATE March 2, 2004 | |
| | EXAMINER Not assigned | CONFIRMATION NO. 3953 | GROUP 1614 | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|------------------------------------------------------------------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BY | C89 | Grasing, K., <i>et al.</i> , "Biphasic Effects of Selegiline on Striatal Dopamine: Lack of Effect on Methamphetamine-Induced Dopamine Depletion," <i>Neurochem. Res.</i> , 26(1):65-74 (2001). |
| | C90 | Gunaratna, C. and Kissinger, P. T., "Investigation of Stereoselective Metabolism of Amphetamine in Rat Liver Microsomes by Microdialysis and Liquid Chromatography with Precolumn Chiral Derivatization," <i>J. Chromatography A</i> , 828:95-103 (1998). |
| | C91 | Gunne, L-M., "The Urinary Output of <i>d</i> - and <i>l</i> -Amphetamine in Man," <i>Biochem. Pharmacol.</i> , 16:863-869 (1967). |
| | C92 | Gyarmati, Z. S., <i>et al.</i> , "Behavioural Consequences of Methamphetamine-Induced Neurotoxicity in Rats," <i>Neurobiology</i> , 9(1):37-39 (2001). |
| | C93 | Haley, T. J., "Desoxyephedrine—A Review of the Literature," <i>J. Am. Pharm. Assoc.</i> , 36(6):161-169 (1947). |
| | C94 | Hardman, J.G., <i>et al.</i> , "Goodman & Gilman's The Pharmacological Basis of Therapeutics," 9 th Edition eds. (NY: McGraw-Hill), pages 202 and 221 (1995). |
| | C95 | Harris, H., <i>et al.</i> , "Behavioral Properties of Amphetaminil Enantiomers," National Institute of Mental Health - 42 nd Annual NCDEU Meeting: Poster Session I [online], July 2002 [retrieved on 2003-03-11]. Retrieved from the Internet <URL: http://www.nimh.nih.gov/ncdeu/abstracts2002/ncdeu1025.cfm >. |
| | C96 | Hart, C. L., <i>et al.</i> , "Methamphetamine Self-administration by Humans," <i>Psychopharmacology</i> , 157:75-81 (2001). |
| | C97 | Hartmann, E. and Cravens, J., "Sleep: Effects of <i>d</i> - and <i>l</i> -Amphetamine in Man and in Rat," <i>Psychopharmacology</i> , 50:171-175 (1976). |
| | C98 | Haughey, H. M., <i>et al.</i> , "Differential Effects of Methamphetamine on NA ⁺ /Cl ⁻ Dependent Transporters," <i>Brain Res.</i> , 863:59-65 (2000). |
| | C99 | Haycock, J. W., <i>et al.</i> , "Effects on Retention of Posttraining Amphetamine Injections in Mice: Interaction with Pretraining Experience," <i>Psychopharmacology</i> , 54:21-24 (1977). |
| ✓ | C100 | Heinonen, E. H., <i>et al.</i> , "Pharmacokinetic Aspects of <i>l</i> -deprenyl (Selegiline) and its Metabolites," <i>Clin. Pharmacol. Ther.</i> 56(6), part 2, 742-749 (1994). |

| | |
|-------------------------------|-------------------------------|
| EXAMINER /Brian Yong Kwon/ | DATE CONSIDERED 01/24/2007 |
|-------------------------------|-------------------------------|

| | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|--|--------------------------------|---------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 3474.1001-011 | | APPLICATION NO.: 10/791,223 | |
| | FIRST NAMED INVENTOR Mel H. Epstein | | FILING DATE March 2, 2004 | |
| | EXAMINER Not assigned | | CONFIRMATION NO. 3953 | GROUP 1614 |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|------------------------------------------------------------------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BY | C101 | Heinonen, E. H., <i>et al.</i> , "Pharmacokinetics and Metabolism of Selegiline," <i>Acta Nerol Scand.</i> , 126:93-99 (1989). |
| | C102 | Herrell, J. M., <i>et al.</i> , "A Multisite Study of the Effectiveness of Methamphetamine Treatment: An Initiative of the Center for Substance Abuse Treatment," <i>J. Psychoactive Drugs</i> , 32(2):143-147 (2000). |
| | C103 | Hornbeck, C. L. and Czarney, R. J., "Retrospective Analysis of Some L-Methamphetamine/L-Amphetamine Urine Data," <i>J. Anal Toxicol.</i> , 17:23-25 (1993). |
| | C104 | Hutchaleelaha, A., <i>et al.</i> , "Disposition Kinetics of <i>d</i> - and <i>l</i> -Amphetamine Following Intravenous Administration of Racemic Amphetamine to Rats," <i>Drug Metab. Dispos.</i> , 22(3):406-411 (1994). |
| | C105 | Itoh, J., <i>et al.</i> , "Utility of an Elevated Plus-Maze for Dissociation of Amnesic and Behavioral Effects of Drugs in Mice," <i>Eur. J. Pharmacol.</i> , 194:71-76 (1991). |
| | C106 | Jelic, V., <i>et al.</i> , "Quantitative Electroencephalography in Mild Cognitive Impairment: Longitudinal Changes and Possible Prediction of Alzheimer's Disease," <i>Neurobiol. of Aging</i> , 21:533-540 (2000). |
| | C107 | Jirovsky, D., <i>et al.</i> , "Methamphetamine - Properties and Analytical Methods of Enantiometer Determination," <i>Forensic Sci. Int.</i> , 96:61-70 (1998). |
| | C108 | Jirovsky, D., <i>et al.</i> , "The Pilot Study of Methamphetamine Enantiometer Metabolism in Man by Capillary Electrophoresis," <i>Chemica</i> , 40:25-34 (2001). |
| | C109 | Johnson, B. A., <i>et al.</i> , "Effects of Isradipine, A Dihydropyridine-Class Calcium Channel Antagonist, on D-Methamphetamine-Induced Cognitive and Physiological Changes in Humans," <i>Neuropharmacology</i> , 22(5):504-512 (2000). |
| | C110 | Jonason, K. R., <i>et al.</i> , "Effects of Amphetamine Upon Relearning Pattern and Black-White Discriminations Following Neocortical Lesions in Rats," <i>J. Comp. Physiol. Psychol.</i> , 73(1):47-55 (1969). |
| | C111 | Jori, A., <i>et al.</i> , "Differences in the Availability of <i>d</i> - and <i>l</i> -Enantiomers after Administration of Racemic Amphetamine to Rats," <i>Xenobiotica</i> , 8(10):589-595 (1978). |
| ✓ | C112 | Karch, S. B., <i>et al.</i> , "Methamphetamine-Related Deaths in San Francisco: Demographic, Pathologic, and Toxicologic Profiles," <i>J. Forensic Sci.</i> , 44(2):359-368 (1999). |

| | |
|-----------------------------------|-----------------------------------|
| EXAMINER /Brian Yong Kwon/ | DATE CONSIDERED 01/24/2007 |
|-----------------------------------|-----------------------------------|

| | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|--|--------------------------------|---------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 3474.1001-011 | | APPLICATION NO.: 10/791,223 | |
| | FIRST NAMED INVENTOR Mel H. Epstein | | FILING DATE March 2, 2004 | |
| | EXAMINER Not assigned | | CONFIRMATION NO. 3953 | GROUP 1614 |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|------------------------------------------------------------------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BY | C113 | Karoum, F., <i>et al.</i> , "Metabolism of (-) Deprenyl to Amphetamine and Methamphetamine May Be Responsible for Deprenyl's Therapeutic Benefit: a Biochemical Assessment," <i>Neurology (Ny)</i> , 32:503-509 (1982). |
| | C114 | Kasirsky, G. and Tansy, M.F., "Teratogenic Effects of Methamphetamine in Mice and Rabbits," <i>Teratology</i> , 4:131-134 (1971). |
| | C115 | Kieburzt, K., <i>et al.</i> , "A Randomized, Double-Blind, Placebo-Controlled Trial of Deprenyl and Thioctic Acid in Human Immunodeficiency Virus-Associated Cognitive Impairment," <i>Neurology</i> , 50:645-651 (1998 March). |
| | C116 | Kikuchi, M., <i>et al.</i> , "EEG Changes Following Scopolamine Administration in Healthy Subjects," <i>Neuropsychobiology</i> 39:219-226 (1999). |
| | C117 | Kim, E. M., <i>et al.</i> , "Determination of Enantiomeric Metabolites of L-deprenyl, d-methamphetamine, and Racemic Methamphetamine in Urine by Capillary Electrophoresis: Comparison of Deprenyl Use and Methamphetamine Use," <i>J. Anal. Toxicol.</i> , 24(4):238-244 (2000). |
| | C118 | Kirrane <i>et al.</i> , "Effects of Amphetamine on Visuospatial Working Memory Performance in Schizophrenia Spectrum Personality Disorder," <i>Neuropsychopharmacology</i> 2000 22(1):14-18 (2000). |
| | C119 | Knoefel, P., "The Influence of Phenisopropyl Amine and Phenisopropyl Methyl Amine on Work Output," <i>Society for Pharmacol. Exp. Ther.</i> , page 83 (1943). |
| | C120 | Knoll, J., "The Possible Mechanisms of Action of (-)Deprenyl in Parkinson's Disease," <i>J. Neural Transm.</i> , 43:177-198 (1978). |
| | C121 | Knoll, J., "The Pharmacology of (-)Deprenyl," <i>J. Neural Transm., (Suppl)</i> , 22:75-89 (1986). |
| | C122 | Kohl, R. L., <i>et al.</i> , "Arousal and Stability: The Effects of five New Sympathomimetic Drugs Suggest a New Principle for the Prevention of Space Motion Sickness," <i>Aviat. Space, Environ. Med.</i> , 137-143 (1986). |
| | C123 | Kopell, B. S., <i>et al.</i> , "The Effects of Methamphetamine and Secobarbital on the Continent Negative Variation Amplitude," <i>Psychopharmacologia (Berl.)</i> , 34:55-62 (1974). |
| ✓ | C124 | Kopell, B. S. and Wittner, W. K., "The Effects of Chlorpromazine and Methamphetamine on Visual Signal-From-Noise Detection," <i>J. Nerv. Ment. Dis.</i> , 147(4):418-424 (1968). |

| | |
|-----------------------------------|-------------------------------|
| EXAMINER /Brian Yong Kwon/ | DATE CONSIDERED 01/24/2007 |
|-----------------------------------|-------------------------------|

| | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|--|--------------------------------|---------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 3474.1001-011 | | APPLICATION NO.: 10/791,223 | |
| | FIRST NAMED INVENTOR Mel H. Epstein | | FILING DATE March 2, 2004 | |
| | EXAMINER Not assigned | | CONFIRMATION NO. 3953 | GROUP 1614 |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|------------------------------------------------------------------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BY | C125 | Kraemer, T. and Maurer, H. H., "Toxicokinetics of Amphetamines: Metabolism and Toxicokinetic Data of Designer Drugs, Amphetamine, Methamphetamine, and Their N-Alkyl Derivatives," <i>Ther. Drug Monit.</i> , 24(2):277-289 (2002). |
| | C126 | Kraemer, T. and Maurer, H. H., "Determination of Amphetamine, Methamphetamine and Amphetamine-derived Designer Drugs or Medicaments in Blood and Urine," <i>J. Chromatogr. B.</i> , 713:163-187 (1998). |
| | C127 | Krivanek, J. A. and McGaugh, J. K., "Facilitation Effects of Pre- and Posttrial Amphetamine Administration on Discrimination Learning in Mice," <i>Agents and Actions</i> , 1:36-42 (1969). |
| | C128 | Kuczenski, R., <i>et al.</i> , "Hippocampus Norepinephrine, Caudate Dopamine and Serotonin, and Behavioral Responses to the Stereoisomers of Amphetamine and Methamphetamine," <i>J. Neurosci.</i> , 15(2):1308-1317 (1995). |
| | C129 | Kuhn, D. M., and Geddes, T. J., "Molecular Footprints and Neurotoxic Amphetamine Action," <i>Ann. N. Y. Acad. Sci.</i> , 914:92-103 (2000). |
| | C130 | Kulig, B. M., and Calhoun, W. H., "Enhancement of Successive Discrimination Reversal Learning by Methamphetamine," <i>Psychopharmacologia (Berl.)</i> , 27:233-240 (1972). |
| | C131 | Kumar, V. and Banker, G. S., "Maillard Reaction and Drug Stability," <i>Maillard Reactions in Chemistry, Food, and Health</i> , 151:20-27 (1994). |
| | C132 | Laine, K., <i>et al.</i> , "Multiple-Dose Pharmacokinetics of Selegiline and Desmethylselegiline Suggest Saturable Tissue Binding," <i>Clin. Neuropharmacol.</i> , 23(1):22-27 (2000). |
| | C133 | Lajtha, A., <i>et al.</i> , "Metabolism of (-)-Deprenyl and PF-(-)-Deprenyl in Brain After Central and Peripheral Administration," <i>Neurochem. Res.</i> , 21(10):1155-1160 (1996). |
| | C134 | Larsen, J. P., <i>et al.</i> , "Does Selegiline Modify the Progression of Early Parkinson's Disease? Results from a Five-year Study," <i>Eur. J. Neurol.</i> , 6:539-547 (1999). |
| | C135 | Law, M. Y. L., "Selective Involvement of Cytochrome P450 2D Subfamily in In Vivo 4-Hydroxylation of Amphetamine in Rat," <i>Drug Metab. Dispos.</i> , 28(3):348-353 (2000). |
| ✓ | C136 | Law, M. Y. L. and Moody, D. E., "Urinary Excretion of Amphetamine and 4'-Hydroxyamphetamine by Sprague Dawley and Dark Agouti Rats," <i>Life Sci.</i> , 54(15):1073-1079 (1994). |

| | |
|-----------------------------------|-----------------------------------|
| EXAMINER /Brian Yong Kwon/ | DATE CONSIDERED 01/24/2007 |
|-----------------------------------|-----------------------------------|

| | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|--|--------------------------------|---------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 3474.1001-011 | | APPLICATION NO.: 10/791,223 | |
| | FIRST NAMED INVENTOR Mel H. Epstein | | FILING DATE March 2, 2004 | |
| | EXAMINER Not assigned | | CONFIRMATION NO. 3953 | GROUP 1614 |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|------------------------------------------------------------------------|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BY | C137 | Lee, E. H. Y. and MA, Y. L., "Amphetamine Enhances Memory Retention and Facilitates Norepinephrine Release from the Hippocampus in Rats," <i>Brain Res. Bull.</i> , 37(4):411-416 (1995). |
| | C138 | Lehmann, H. E. and Ban, T. A., "Effects of Psychoactive Drugs on Conflict Avoidance Behavior in Human Subjects," <i>Activitas nervosa superior</i> , 13(2):82-85 (1971). |
| | C139 | Lehmann, H. E., <i>et al.</i> , "The Effect of Psychostimulants on Psychometric Test Performance With Special Reference to Conflict Avoidance Behavior," <i>Curr. Ther. Res.</i> , 12(6):390-393 (1970). |
| | C140 | Lin, L. Y., <i>et al.</i> , "Cytochrome P4502D Isozymes Catalyze the 4-Hydroxylation of Methamphetamine Enantiomers," <i>Drug Metab. Dispos.</i> , 23(6):610-614 (1995). |
| | C141 | Lin, J. S., <i>et al.</i> , "Effects of Amphetamine and Modafinil on the Sleep/Wake Cycle During Experimental Hypersomnia Induced by Sleep Deprivation in the Cat," <i>J. Sleep Res.</i> , 9(1):89-96. |
| | C142 | Lokiec, F., <i>et al.</i> , "A Comparison of the Kinetics of <i>d</i> - and <i>l</i> -Amphetamine in the Brain of Isolated and Aggregated Rats," <i>Psychopharmacology</i> 58:73-77 (1978). |
| | C143 | M'Harzi, M., <i>et al.</i> , "d-Amphetamine Enhances Memory Performance in Rats with Damage to the Fimbria," <i>Physiol. Behav.</i> , 42:575-579 (1988). |
| | C144 | Magidson, O.Y., and Garkusha, G.A., "The Synthesis of 2-phenylisopropylamine (phenamine)," <i>Chemical Abstracts</i> 35, 5868 (1941). |
| | C145 | Mangoni, A. "Effects of a MAO-B Inhibitor in the Treatment of Alzheimer Disease," <i>Eur Neurol.</i> 31: 100-107 (1991). |
| | C146 | Mann, J. J., <i>et al.</i> , "A Controlled Study of the Antidepressant Efficacy and Side Effects of (-)-Deprenyl," <i>Arch. Gen. Psychiatry</i> , 46:45-50 (1989). |
| | C147 | Martin, W. R., <i>et al.</i> , "Physiologic, Subjective, and Behavioral Effects of Amphetamine, Methamphetamine, Ephedrine, Phenmetrazine, and Methylphenidate in Man," <i>Clin. Pharmacol. Ther.</i> , 12(2):245-258 (1970). |
| ✓ | C148 | Martinez, J. L., <i>et al.</i> , "Central and Peripheral Actions of Amphetamine on Memory Storage," <i>Brain Research</i> , 182:157-166 (1980). |

| | |
|-----------------------------------|-----------------------------------|
| EXAMINER /Brian Yong Kwon/ | DATE CONSIDERED 01/24/2007 |
|-----------------------------------|-----------------------------------|

| | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|--------------------------|--------------------------------|--|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 3474.1001-011 | | APPLICATION NO.: 10/791,223 | |
| | FIRST NAMED INVENTOR Mel H. Epstein | | FILING DATE March 2, 2004 | |
| | EXAMINER Not assigned | CONFIRMATION NO. 3953 | GROUP 1614 | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|------------------------------------------------------------------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BY | C149 | Maruyama, W. and Naoi, M., "Neuroprotection by (-)-deprenyl and Related Compounds," <i>Mech. Ageing Dev.</i> , 111:189-200 (1999). |
| | C150 | Matsubara, K., <i>et al.</i> , "L-Deprenyl Prevents the Cell Hypoxia Induced by Dopaminergic Neurotoxins, Mpp+ and β -carbolinium: a Microdialysis Study in Rats," <i>Neuroscience Lett.</i> , 302:65-68 (2001). |
| | C151 | Matthews, C., "Overweight Relapse: Effects of Training and Methamphetamine with Pentobarbital," <i>Curr. Ther. Res.</i> , 12(1):34-39 (1970). |
| | C152 | Mayfield, D. G., "The Effect of Intravenous Methamphetamine on Mood," <i>Int. J. Addict.</i> , 8(3):565-568 (1973). |
| | C153 | McIntyre, H. B., "Computer Analyzed EEG in Amphetamine-Responsive Hyperactive Children," <i>Psychiatry Res.</i> , 4:189-197 (1981). |
| | C154 | Melega, W. P., <i>et al.</i> , "Pharmacokinetic and Pharmacodynamic Analysis of the Actions of D-Amphetamine and D-Methamphetamine on the Dopamine Terminal," <i>J. Pharmacol. Exp. Ther.</i> , 274(1): 90-96 (1995). |
| | C155 | Melega, W. P., <i>et al.</i> , "l-Methamphetamine Pharmacokinetics and Pharmacodynamics for Assessment of <i>in vivo</i> Deprenyl-Derived l-Methamphetamine," <i>J. Pharmacol. Exp. Ther.</i> , 288(2):752-758 (1999). |
| | C156 | Melega, W. P., <i>et al.</i> , "Effects of Deprenyl Metabolite, L-Methamphetamine on Striatal Dopamine Efflux," <i>Neurotransmission, Neuromodulation</i> , A376, Abstract No. 2177. |
| | C157 | Metcalf, F. U., <i>et al.</i> , "Methamphetamine Effects Upon Avoidance Behavior during Limbic Seizures in the Cat," <i>Psychopharmacologia (Berl.)</i> , 21:390-400 (1971). |
| | C158 | Mewaldt, S. P., and Ghoneim, M. M., "The Effects and Interactions of Scopolamine, Physostigmine and Methamphetamine on Human Memory," <i>Pharmacol. Biochem. Behav.</i> , 10:205-210 (1979). |
| | C159 | Milgram, N. W., <i>et al.</i> , "The Effect of L-Deprenyl on Behavior, Cognitive Function, and Biogenic amines in the Dog," <i>Neurochem. Res.</i> , 18(12):1211-1219 (1993). |
| ✓ | C160 | Mills, D. and Ledger, R., "The Effects of Oral Selegiline Hydrochloride on Learning and Training in the Dog: A Psychobiological Interpretation," <i>Prog. Neuro-Psychopharmacol. & Biol. Psychiat.</i> , 25:1597-1613 (2001). |

| | |
|-----------------------------------|-------------------------------|
| EXAMINER /Brian Yong Kwon/ | DATE CONSIDERED 01/24/2007 |
|-----------------------------------|-------------------------------|

| | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|--|--------------------------------|---------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 3474.1001-011 | | APPLICATION NO.: 10/791,223 | |
| | FIRST NAMED INVENTOR Mel H. Epstein | | FILING DATE March 2, 2004 | |
| | EXAMINER Not assigned | | CONFIRMATION NO. 3953 | GROUP 1614 |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|------------------------------------------------------------------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BY | C161 | Miyamoto, K., "Conditioned Drug Effects of Pimozide, Haloperidol and Chlorpromazine on Methamphetamine-Induced Behavior," <i>Japanese J. Psychiat. Neurol.</i> , 44(3):629-636 (1990). |
| | C162 | Mohs, R. C., <i>et al.</i> , "Sensitivity of Some Human Cognitive Functions to Effects of Methamphetamine and Secobarbital," <i>Drug and Alcohol Depend.</i> , 5:145-150 (1980). |
| | C163 | Mohs, R. C., <i>et al.</i> , "Methamphetamine and Diphenhydramine Effects on the Rate of Cognitive Processing," <i>Psychopharmacology</i> , 59:13-19 (1978). |
| | C164 | Monmaur, P., <i>et al.</i> , "Involvement of Septal Muscarinic Receptors in Cholinergically Mediated Changes in Rat Rearing Activity," <i>Pharmacol. Biochem. Behav.</i> , 58(2):577-582 (1997). |
| | C165 | Moretti, R., <i>et al.</i> , "Effects of Selegiline on Fronto-temporal Dementia: a Neuropsychological Evaluation," <i>Int. J. Geriatr. Psychiatry</i> , 17:391-392 (2002). |
| | C166 | Muller, H., <i>et al.</i> , "Rey Auditory-Verbal Learning Test: Structure of a Modified German Version," <i>Jornal of Clinical Psychology</i> , 53(7):663-671 (1997). |
| | C167 | Munzar, P., <i>et al.</i> , "Potentiation of the Discriminative-stimulus Effects of Methamphetamine by the Histamine H ₃ Receptor Antagonist Thioperamide in Rats," <i>Eur. J. Pharmacol.</i> , 363:93-101 (1998). |
| | C168 | Musshoff, F., "Illegal or Legitimate Use? Precursor Compounds to Amphetamine and Methamphetamine," <i>Drug Metab. Rev.</i> , 32(1):15-44 (2000). |
| | C169 | Myers, C.E., <i>et al.</i> , "Impaired Delay Eyeblink Classical Conditioning in Individuals With Anterograde Amnesia Resulting From Anterior Communicating Artery Aneurysm Rupture," <i>Behav. Neurosci.</i> , 115(3):560-570 (2001). |
| | C170 | Nickel, B., <i>et al.</i> , "Effect of Enantiomers of Deprenyl (Selegiline) and Amphetamine on Physical Abuse Liability and Cortical Electrical Activity in Rats," <i>Neuropharmacology</i> , 29(11):983-992 (1990). |
| | C171 | Nicolaus, B. J. R., "Symbiotic Approach to Drug Design," <i>Decision Making in Drug Research</i> , pp. 173-186 (1983). |
| | C172 | Ogata, A., "Constitution of Ephedrine," <i>Chemical Abstracts</i> 14, 745 (1920). |
| ✓ | C173 | Ong, Y. L., <i>et al.</i> , "Suppression of Bulimic Symptoms with Methylamphetamine," <i>Brit. J. Psychiat.</i> , 143: 288-293 (1983). |

| | |
|-----------------------------------|-----------------------------------|
| EXAMINER /Brian Yong Kwon/ | DATE CONSIDERED 01/24/2007 |
|-----------------------------------|-----------------------------------|

| | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|--|--------------------------------|---------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 3474.1001-011 | | APPLICATION NO.: 10/791,223 | |
| | FIRST NAMED INVENTOR Mel H. Epstein | | FILING DATE March 2, 2004 | |
| | EXAMINER Not assigned | | CONFIRMATION NO. 3953 | GROUP 1614 |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|------------------------------------------------------------------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BY | C174 | Ozaki, T., <i>et al.</i> , "The Adverse Effects of l-Methamphetamine on the Development of Explanted Rat Embryos," <i>Asia-Oceania Journal Obstet. Gynaecol.</i> 18(3):277-281 (1992). |
| | C175 | Parkes, J. D., <i>et al.</i> , "Amphetamines in the Treatment of Parkinson's Disease," <i>J. Neurol., Neurosurg., Psychiat.</i> , 38:232-237 (1975). |
| | C176 | Parkes, J. D. and Fenton, G. W., "Levo(-) Amphetamine and Dextro(+) Amphetamine in the Treatment of Narcolepsy," <i>J. Neurol., Neurosurg., Psychiat.</i> , 36:1076-1081 (1973). |
| | C177 | Parkinson Study Group, "Impact of Deprenyl and Tocopherol Treatment on Parkinson's Disease in DATATOP Subjects Not Requiring Levodopa," <i>Ann. Neurol.</i> , 39(1):29-36 (1996). |
| | C178 | Penetar, D. M., <i>et al.</i> , "Amphetamine Effects on Recovery Sleep Following Total Sleep Deprivation," <i>Human Psychopharmacology</i> , 6:319-323 (1991). |
| | C179 | Pepeu, G., "Memory Disorders: Novel Treatments, Clinical Perspective," <i>Life Sci.</i> , 55(25-26):2189-2194 (1994). |
| | C180 | Perez-Reyes, M., <i>et al.</i> , "Clinical Effects of Methamphetamine Vapor Inhalation," <i>Life Sci.</i> , 49(13):953-959 (1991). |
| | C181 | Perez-Reyes, M., "Differences in Sedative Susceptibility Between Types of Depression," <i>Arch. Gen. Psychiat.</i> , 19:64-71 (1968). |
| | C182 | <i>Physician Desk Reference</i> 946, 1221 (1969). |
| | C183 | Pitsikas, N., <i>et al.</i> , "Effect of Org2766, an ACTH(4-9) Analogue, on Recovery After Bilateral Transection of the Fimbria Fornix in the Rat," <i>Pharmacol. Biochem. Behav.</i> , 38:931-934 (1991). |
| | C184 | Pitsikas, N., <i>et al.</i> , "DAU 6215, A Novel 5-HT ₃ Receptor Antagonist, Improves Performance in the Aged Rat in the Morris Water Maze Task," <i>Neurobiol. of Aging</i> 14:561-564 (1993). |
| | C185 | Plasznik, A. and Kostowski, W., "Effects of p-Bromo-Methamphetamine (V-111) on Conditioned Avoidance Behavior in Rats with Lesioned <i>Raphe Nuclei</i> ," <i>Fol. J. Pharmacol. Pharm.</i> 21, 193-198 (1997). |
| ✓ | C186 | Platel, A. and Porsolt, R. D., "Habituation of Exploratory Activity in Mice: A Screening Test for Memory Enhancing Drugs," <i>Psychopharmacology</i> , 78:346-352 (1982). |

| | |
|----------------------------|----------------------------|
| EXAMINER /Brian Yong Kwon/ | DATE CONSIDERED 01/24/2007 |
|----------------------------|----------------------------|

| | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|--------------------------|--------------------------------|--|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 3474.1001-011 | | APPLICATION NO.: 10/791,223 | |
| | FIRST NAMED INVENTOR Mel H. Epstein | | FILING DATE March 2, 2004 | |
| | EXAMINER Not assigned | CONFIRMATION NO. 3953 | GROUP 1614 | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|------------------------------------------------------------------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BY | C187 | Prinzmetal, M. and Alles, G. A., "The Central Nervous System Stimulant Effects of Dextro-Amphetamine Sulphate," 200(5):665-673 (1940). |
| | C188 | Przuntek, H., <i>et al.</i> , "SELEDO: a 5-year Long-term Trial on the Effect of Selegiline in Early Parkinsonian Patients Treated with Levodopa," <i>Eur. J. Neurology</i> , 6:141-150 (1999). |
| | C189 | Quartermain, D., <i>et al.</i> , "Amphetamine Enhances Retrieval Following Diverse Sources of Forgetting," <i>Physiol. Behav.</i> , 43:239-241 (1988). |
| | C190 | Quartermain, D. and Altman, H. J., "Facilitation of Retrieval by d-Amphetamine Following Anisomycin-Induced Amnesia," <i>Physiol. Psychol.</i> , 10(3):283-292 (1982). |
| | C191 | Quartermain, D. and Jung, H., "Persistence of Retrieval Enhancement by Amphetamine Following Scopolamine-Induced Amnesia," <i>Pharmacol. Biochem. Behav.</i> , 33:51-54 (1989). |
| | C192 | Quartermain, D., <i>et al.</i> , "Alleviation of Scopolamine Amnesia by Different Retrieval Enhancing Treatments," <i>Pharmacol. Biochem. Behav.</i> 30(4):1093-1096 (1988). |
| | C193 | Ramos, J., <i>et al.</i> , "EEG Activity During Cognitive Performance in Women," <i>Intern. J. Neurosci.</i> , 69:185-195 (1993). |
| | C194 | Reus, V. I., <i>et al.</i> , "d-Amphetamine: Effects on Memory in a Depressed Population," <i>Biol. Psychol.</i> , 14(2):345-356 (1979). |
| | C195 | Reynolds, G. P., <i>et al.</i> , "Deprenyl is Metabolized to Methamphetamine and Amphetamine in Man," <i>Br. J. Clin. Pharmacol.</i> , 6:542-544 (1978). |
| | C196 | Richards, J. B., <i>et al.</i> , "Trained and Amphetamine-Induced Circling Behavior in Lesioned, Transplanted Rats," <i>J. Neural Transplantation & Plasticity</i> , 4(2):157-166 (1993). |
| | C197 | Richter, D., "CCXXIX. Elimination of Amines in Man," <i>Biochem. J.</i> , 32:1763-1769 (1938). |
| | C198 | Richter-Levin, G. and Yaniv, D., "Is LTP in the Hippocampus a Useful Model for Learning-Related Alterations in Gene Expression?," <i>Reviews in Neurosciences</i> , 12:289-296 (2001). |
| ↓ | C199 | Riederer, P. and Przuntek, H. (eds.), "MAO-B-Inhibitor Selegiline (R-(-)-Deprenyl), A New Therapeutic Concept in the Treatment of Parkinson's Disease," <i>J. Neural Transm., Supp.</i> 25: (1987). |

| | |
|-------------------------------|----------------------------|
| EXAMINER /Brian Yong Kwon/ | DATE CONSIDERED 01/24/2007 |
|-------------------------------|----------------------------|

| | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|--------------------------|--------------------------------|--|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 3474.1001-011 | | APPLICATION NO.: 10/791,223 | |
| | FIRST NAMED INVENTOR Mel H. Epstein | | FILING DATE March 2, 2004 | |
| | EXAMINER Not assigned | CONFIRMATION NO. 3953 | GROUP 1614 | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|------------------------------------------------------------------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BY | C200 | Riederer, P., <i>et al.</i> , "On the Mode of Action of L-Deprenyl in the Human Central Nervous System," <i>J. Neural Transm.</i> , 43:217-226 (1978). |
| | C201 | Riekkinen, Jr., P., <i>et al.</i> , "Effects of Alzene and Tacrine on Water Maze Reference and Working Memory Function in Medial Septal-Lesioned Rats," <i>Brain Res.</i> , 714:118-124 (1996). |
| | C202 | Riley, D. E., "Reversible Transvestic Fetishism in a Man With Parkinson's Disease Treated With Selegiline," <i>Clin. Neuropharmacol.</i> , 25(4):234-237 (2002). |
| | C203 | Riviere, G. J., <i>et al.</i> , "Disposition of Methamphetamine and Its Metabolite Amphetamine in Brain and Other Tissues in Rats after Intravenous Administration," <i>J. Pharmacol. Exp. Ther.</i> , 292(3):1042-1047 (2000). |
| | C204 | Riviere, G. J., <i>et al.</i> , "Spontaneous Locomotor Activity and Pharmacokinetics of Intravenous Methamphetamine and Its Metabolite Amphetamine in the Rat," <i>J. Pharmacol. Exp. Ther.</i> , 291(3):1220-1226 (1999). |
| | C205 | Roth, L. W., <i>et al.</i> , "A Comparison of the Analeptic, Circulatory and Other Properties of D- and L-Desoxyephedrine," <i>Arch. Int. Pharmacodyn.</i> , XCVII(3):362-368 (1954). |
| | C206 | Sainsbury, R. S., "Hippocampal Theta: A Sensory-Inhibition Theory of Function," <i>Neurosc. Biobehav. Rev.</i> , 22(2):237-241 (1998). |
| | C207 | Sanders-Bush, E. and Sulser, F., "Metabolic and Neurochemical Aspects of the Pharmacology of Amphetamine and Para-Chloroamphetamine," Chapter 8, pp 69-70. |
| | C208 | Sano, M., <i>et al.</i> , "A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease," <i>NEJM</i> , 336(17):1216-1222 (1997). |
| | C209 | Sansone, M., <i>et al.</i> , "Interaction between Nootropic Drugs and Methamphetamine on Avoidance Acquisition but not on Locomotor Activity in Mice," <i>Arch. Int. Pharmacodyn.</i> , 278:229-235 (1985). |
| | C210 | Sansone, M., <i>et al.</i> , "Minaprine, but not Oxiracetam, Prevents Desipramine-Induced Impairment of Avoidance Learning in Mice," <i>Pol. J. Pharmacol.</i> 47:69-73 (1995). |
| ✓ | C211 | Sara, S. J. and Deweer, B., "Memory Retrieval Enhanced by Amphetamine After a Long Retention Interval," <i>Behavioral and Neural Biology</i> , 36:146-160 (1982). |

| | |
|-------------------------------|-------------------------------|
| EXAMINER /Brian Yong Kwon/ | DATE CONSIDERED 01/24/2007 |
|-------------------------------|-------------------------------|

| | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|--------------------------|--------------------------------|--|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 3474.1001-011 | | APPLICATION NO.: 10/791,223 | |
| | FIRST NAMED INVENTOR Mel H. Epstein | | FILING DATE March 2, 2004 | |
| | EXAMINER Not assigned | CONFIRMATION NO. 3953 | GROUP 1614 | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|------------------------------------------------------------------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BY | C212 | Sarter, M., "Behavioral Screening for Cognition Enhancers from Indiscriminate to Valid Testing: Part II," <i>Psychopharmacology</i> , 107:461-473 (1992). |
| | C213 | Sarter, M., "Behavioral Screening for Cognition Enhancers: from Indiscriminate to Valid Testing: Part I," <i>Psychopharmacology</i> , 107:144-158 (1992). |
| | C214 | Satoh, M., <i>et al.</i> , "A Pharmacological Profile of LTP in CA3 Region of Guinea-Pig Hippocampus <i>In Vitro</i> ," <i>Biomedical Research</i> , 10(2):125-129, 1989. |
| | C215 | Schachter, M., <i>et al.</i> , "Deprenyl in the Management of Response Fluctuations in Patients with Parkinson's Disease on Levodopa," <i>J. Neurol., Neurosurg., Psychiatry</i> , 43:1016-1021 (1980). |
| | C216 | Scheinin, H., <i>et al.</i> , "CYP2D6 Polymorphism is Not Crucial for the Disposition of Selegiline," <i>Clin. Pharmacol. Ther.</i> , 64(4):402-411 (1998). |
| | C217 | Shappell, S. A., <i>et al.</i> , "Stimulated Sustained Flight Operations and Performance, Part 2: Effects of Dextro-Methamphetamine," <i>Military Psychology</i> , 4(4), 267-287 (2002). |
| | C218 | Shimada, A., <i>et al.</i> , "Neurochemical Analysis of the Psychotoxicity of Methamphetamine and Cocaine by Microdialysis in the Rat Brain," <i>Ann. N. Y. Acad. Sci.</i> , 801(1):361-370 (1996). |
| | C219 | Shimosato, K., "Urinary Excretion of <i>p</i> -Hydroxylated Methamphetamine Metabolites in Man. II. Effect of Alcohol Intake on Methamphetamine Metabolism," <i>Pharmacol. Biochem. Behav.</i> , 29: 733-740 (1988). |
| | C220 | Shutter, L. and Garell, D. C., "Obesity in Children and Adolescents: A Double-Blind Study with Cross-Over," <i>J. Sch. Health</i> , 273-275 (1966). |
| | C221 | Sim, T., <i>et al.</i> , "Cognitive Deficits Among Methamphetamine Users with Attention Deficit Hyperactivity Disorder Symptomatology," <i>J. Addict. Dis.</i> , 21(1):75-89 (2002). |
| | C222 | Simpson, L. L., "Blood Pressure and Heart Rate Responses Evoked by <i>d</i> - and <i>l</i> -Amphetamine in the Pithed Rat Preparation," <i>J. Pharmacol. Exp. Ther.</i> , 193:149-159 (1975). |
| | C223 | Simpson, L. L., "Evidence That Deprenyl, A Type B Monoamine Oxidase Inhibitor, Is an Indirectly Acting Sympathomimetic Amine," <i>Biochem. Pharmacol.</i> , 27:1591-1595 (1978). |
| ✓ | C224 | Smith, R. C., <i>et al.</i> , "Comparative Effects of <i>d</i> -Amphetamine, <i>l</i> -Amphetamine, and Methylphenidate on Mood in Man," <i>Psychopharmacology</i> 53:1-12 (1977). |

| | |
|-------------------------------|----------------------------|
| EXAMINER /Brian Yong Kwon/ | DATE CONSIDERED 01/24/2007 |
|-------------------------------|----------------------------|

| | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 3474.1001-011 FIRST NAMED INVENTOR Mel H. Epstein EXAMINER Not assigned | APPLICATION NO.: 10/791,223 FILING DATE March 2, 2004 CONFIRMATION NO. 3953 GROUP 1614 |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|------------------------------------------------------------------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BY | C225 | Soetens, E., <i>et al.</i> , "Effect of Amphetamine on Long-Term Retention of Verbal Material," <i>Psychopharmacology</i> , 119:155-162 (1995). |
| | C226 | Soetens, E., <i>et al.</i> , "Amphetamine Enhances Human-Memory Consolidation," <i>Neurosci. Lett.</i> 161:9-12 (1993). |
| | C227 | Song, J. K., <i>et al.</i> , "Neuroradiologic Diagnosis and Treatment of Vasospasm," <i>Cerebral Aneurysms</i> , 7(4):819-835 (1997). |
| | C228 | Sprague, J. E. and Nichols, D. E., "The Monoamine Oxidase-B Inhibitor L-Deprenyl Protects Against 3,4-Methylenedioxymethamphetamine-Induced Lipid Peroxidation and Long-term Serotonergic Deficits," <i>J. Pharmacol. Exp. Ther.</i> , 273(2):667-673 (1995). |
| | C229 | Squire, L. R., "Cerebral Protein Synthesis Inhibition and Discrimination Training: Effects of D-amphetamine," <i>Brain Res.</i> , 177:401-406 (1999). |
| | C230 | Stein, L., <i>et al.</i> , "Memory Enhancement by Central Administration of Norepinephrine," <i>Brain Res.</i> 84(1):329-335 (1975). |
| | C231 | Strupp, B. J., <i>et al.</i> , "Time-Dependent Effects of Post-Trial Amphetamine Treatment in Rats: Evidence for Enhanced Storage of Representational Memory," <i>Behav. Neural. Biol.</i> , 56:62-76 (1991). |
| | C232 | Szende, B., <i>et al.</i> , "Anti-apoptotic and Apoptotic Action of (-)-deprenyl and its Metabolites," <i>J. Neural. Transm.</i> , 108:25-33 (2001). |
| | C233 | Szoko, E., <i>et al.</i> , "Biotransformation of Deprenyl Enantiomers," <i>Eur. J. Drug Metab. Pharmacokinet.</i> , 24(4):315-319 (1999). |
| | C234 | Tariot, P. N., <i>et al.</i> , "Cognitive effects of L-deprenyl in Alzheimer's Disease," <i>Psychopharmacology</i> , 91:489-495 (1987). |
| | C235 | Tariot, P. N., <i>et al.</i> , "L-Deprenyl in Alzheimer's Disease," <i>Arch. Gen. Psychiatry</i> , 44:427-433 (1987). |
| | C236 | Tatton, W. G., "Selegiline Can Mediate Neuronal Rescue Rather Than Neuronal Protection," <i>Movement Disorder Society</i> , 8(Supp. 1):S20-S30 (1993). |
| ✓ | C237 | Teter, D. F., "Metabolism of Diet Pill to Amphetamine and Methamphetamine," (Letters to the Editor), <i>JOEM</i> , 41(3):139 (1999). |

| | |
|-------------------------------|-------------------------------|
| EXAMINER /Brian Yong Kwon/ | DATE CONSIDERED 01/24/2007 |
|-------------------------------|-------------------------------|

| | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 3474.1001-011 FIRST NAMED INVENTOR Mel H. Epstein EXAMINER Not assigned | APPLICATION NO.: 10/791,223 FILING DATE March 2, 2004 CONFIRMATION NO. 3953 GROUP 1614 |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------|

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|------------------------------------------------------------------------|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BY | C238 | ThyagaRajan, S., <i>et al.</i> , "Region-specific Alterations in the Concentrations of Catecholamines and Indoleamines in the Brains of Young and Old F344 Rats after L-deprenyl Treatment," <i>Brain Res. Bull.</i> , 48(5):513-520 (1999). |
| | C239 | Van Rijzingen, I. M. S., "ACTH(4-9) Analog ORG2766 Treatment 7 Months Delayed Still Improves Morris Maze Performance of Fimbria-Lesioned Rats," <i>Pharmacol. Biochem. Behav.</i> , 53(1):163-169 (1996). |
| | C240 | Van Alvea, O. E., and Donnelly, W. A., "Systemic Effects of Intranasal Medication," <i>Eye, Ear, Nose & Throat Monthly</i> , 31:476-480 (1952). |
| | C241 | Van Kammen, D. P. and Murphy, D. L., "Attenuation of the Euphoriant and Activating Effects of <i>d</i> - and <i>l</i> -Amphetamine by Lithium Carbonate Treatment," <i>Psychopharmacologia (Berl.)</i> , 44:215-224 (1975). |
| | C242 | Vidrio, H., "Cardiovascular Effects of Methamphetamine in Dogs Treated Chronically with the Amine," <i>J. Cardiovas. Pharmacol.</i> , 4(2):326-329 (1982). |
| | C243 | Volkow, N. D., <i>et al.</i> , "Loss of Dopamine Transporters in Methamphetamine Abusers Recovers with Protracted Abstinence," <i>J. Neurosci.</i> , 21(23):9414-9418 (2001). |
| | C244 | Vorhees, C. V., <i>et al.</i> , "Adult Learning Deficits After Neonatal Exposure to D-Methamphetamine: Selective Effects on Spatial Navigation and Memory," <i>J. Neurosci.</i> , 20(12):4732-4739 (2000). |
| | C245 | Vree, T. B., and van Rossum, J. M., "Kinetics of Metabolism and Excretion of Amphetamines in Man," in <i>Amphetamines and Related Compounds</i> , Costa and Garattini, eds. (Rave Press, NY) pp. 165-190 (1970). |
| | C246 | Walter-Batson, D., <i>et al.</i> , "Amphetamine Paired with Physical Therapy Accelerates Motor Recovery After Stroke," <i>Stroke</i> , 26(12):2254-2259 (1995). |
| | C247 | Wan, S. H., <i>et al.</i> , "Kinetics, Salivary Excretion of Amphetamine Isomers, and Effect of Urinary pH," <i>Clin. Pharmacol. Ther.</i> , 23(5):585-590 (1978). |
| | C248 | Wang, J. Q. and McGinty, J. F., "Dose-Dependent Alteration in <i>zif/268</i> and Preprodynorphin mRNA Expression Induced by Amphetamine or Methamphetamine in Rat Forebrain," <i>J. Pharmacol. Exp. Ther.</i> , 273(2):909-917 (1995). |
| ✓ | C249 | Wiegmann, D. A., <i>et al.</i> , "Methamphetamine Effects on Cognitive Processing During Extended Wakefulness," <i>Int. J. Aviat. Psychol.</i> , 6(4):379-397 (1996). |

| | |
|-------------------------------|-------------------------------|
| EXAMINER /Brian Yong Kwon/ | DATE CONSIDERED 01/24/2007 |
|-------------------------------|-------------------------------|

| | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|--------------------------|--------------------------------|--|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 3474.1001-011 | | APPLICATION NO.: 10/791,223 | |
| | FIRST NAMED INVENTOR Mel H. Epstein | | FILING DATE March 2, 2004 | |
| | EXAMINER Not assigned | CONFIRMATION NO. 3953 | GROUP 1614 | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|------------------------------------------------------------------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BY | C250 | Wilcock, G. K., <i>et al.</i> , "The Effect of Selegiline in the Treatment of People with Alzheimer's Disease: a Meta-analysis of Published Trials," <i>Int. J. Geriatr. Psychiatry</i> 17:175-183 (2002). |
| | C251 | Witkin, J. M. <i>et al.</i> , "Behavioral, Toxic and Neurochemical Effects of Sydnocarb, a Novel Psychomotor Stimulant: Comparisons with Methamphetamine," <i>Pharmacol. Exp. Ther.</i> , 288(3):1298-1310 (1999). |
| | C252 | Wolthuis, O. L., "Experiments With UCB 6215, A Drug Which Enhances Acquisition In Rats: Its Effects Compared With Those of Metamphetamine," <i>Eur. J. Pharmacol.</i> , 16:283-297 (1971). |
| | C253 | Yamamoto, R., and Takasaki, K., "Involvement of Presynaptic α_2 -Adrenoreceptors in the Depressor Response Produced by Repeated Administration of Dextro-Methamphetamine," <i>J. Auton. Pharmac.</i> , 3: 79-88 (1983). |
| | C254 | Yamamura, T., <i>et al.</i> , "Effects of Methamphetamine and Ethanol on Learning and Brain Neurotransmitters in Rats," <i>Pharmacol. Biochem. Behav.</i> , 42:389-400 (1992). |
| | C255 | Yamamura, T., <i>et al.</i> , "Effects of Daily Administration of Methamphetamine on Multiple Active/Passive Avoidance Performance in Rats," <i>Behav. Brain Res.</i> , 53:105-112 (1993). |
| | C256 | Yanagisawa, Y., <i>et al.</i> , "Association Equilibrium of <i>d</i> -Methamphetamine and <i>l</i> -Methamphetamine With Serum Albumin," <i>Chirality</i> 10:742-746 (1998). |
| | C257 | Yasar, S., <i>et al.</i> , "Are Metabolites of <i>l</i> -deprenyl (Selegiline) Useful or Harmful? Indications From Preclinical Research," <i>J. Neurol. Transmission [suppl 48]</i> , Springer Verlag, Wein, New York, pp. 61-73 (1996). |
| | C258 | Yasar, S. and Bergman, J., "Amphetamine-like effect of <i>l</i> -deprenyl (selegiline) in Drug Discrimination Studies," <i>Clin. Pharmacol. Ther.</i> , 56(6):768-773 (1994). |
| | C259 | Yasar, S. <i>et al.</i> , "Evaluation of the Stereoisomers of Deprenyl for Amphetamine-Like Discriminative Stimulus Effects in Rats," <i>J. Pharmacol. Exp. Ther.</i> , 265(1):1-6 (1993). |
| | C260 | Yasar, S., <i>et al.</i> , "Preclinical Evaluation of <i>l</i> -Deprenyl: Lack of Amphetamine-Like Abuse Potential," <i>Inhibitors of Monoamine Oxidase B Pharmacology and Clinical Uses in Neurodegenerative Disorders</i> , I. Szelenyi, ed. (Switzerland: Birkhauser Verlag Basel), pp. 215-233 (1993). |
| ✓ | C261 | Yi-Ping, H., "Effects of Modafinil and Amphetamine on Sleep-Wake Cycle After Sleep Deprivation in Cats," <i>Acta Pharmacol Sin</i> , 20(9):813-818 (1999). |

| | |
|-----------------------------------|-----------------------------------|
| EXAMINER /Brian Yong Kwon/ | DATE CONSIDERED 01/24/2007 |
|-----------------------------------|-----------------------------------|

| | | | | |
|--------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|--------------------------|--------------------------------|--|
| PTO-1449 REPRODUCED INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION June 19, 2006 (Use several sheets if necessary) | ATTORNEY DOCKET NO. 3474.1001-011 | | APPLICATION NO.: 10/791,223 | |
| | FIRST NAMED INVENTOR Mel H. Epstein | | FILING DATE March 2, 2004 | |
| | EXAMINER Not assigned | CONFIRMATION NO. 3953 | GROUP 1614 | |

| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | |
|------------------------------------------------------------------------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BY | C262 | Yokel, R. A. and Pickens, R., "Self-Administration of Optical Isomers of Amphetamine and Methylamphetamine by Rats," <i>J. Pharmacol. Exp. Ther.</i> , 187(1):27-33 (1973). |
| | C263 | Yonkov, D. I., "Participation of Cholinergic Mechanisms in The Memory Effects of CNS Stimulants," <i>Advanced In The Bioscience, Pergamon Press, GB.</i> , 59:347-350 (1986). |
| | C264 | Yoshida, T., <i>et al.</i> , "Metabolism of Deprenyl, a Selective Monoamine Oxidase (MAO) B Inhibitor in Rat: Relationship of Metabolism to MAO- β Inhibitory Potency," <i>Xenobiotica</i> , 16(2):129-136 (1986). |
| | C265 | Young, G. A., "Relationship Between Amphetamine-Induced Effects on EEG Power Spectra and Motor Activity in Rats," <i>Pharmacology Biochemistry & Behavior</i> 30:489-492 (1988). |
| | C266 | Yui, K., <i>et al.</i> , "Noradrenergic Activity and Spontaneous Recurrence of Methamphetamine Psychosis," <i>Drug and Alcohol Depend.</i> , 44: 183-187 (1997). |
| | C267 | Yui, K. and Miura, T., "Behavioral Responses Induced by Repeated Treatment with Methamphetamine Alone and in Combination with Scopolamine in Rats," <i>Neuropsychobiology</i> , 33:21-27 (1996). |
| ↓ | C268 | Zink, W. E., <i>et al.</i> , "Model Systems for Assessing Cognitive Function: Implications for HIV-1 Infection and Drugs of Abuse," <i>Neuroimmune Circuits, Drugs of Abuse, and Infectious Diseases</i> , 7-27 (2001). |

| | |
|-----------------------------------|-----------------------------------|
| EXAMINER /Brian Yong Kwon/ | DATE CONSIDERED 01/24/2007 |
|-----------------------------------|-----------------------------------|